Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Strategic focus on COCO-model with a nationwide reach of 501 stores
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
India has taken the lead in recognising NAFLD as a major non-communicable disease
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Subscribe To Our Newsletter & Stay Updated
